21 May 2018
News and Views
Links and Services
Cardiovascular risk reduction in patients with nonalcoholic fatty liver disease using ezetimibe, reports the latest issue of the Digestive Diseases & Sciences.
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors